{"product_id":"new-product-615951","title":"Magnetic Luminex Assay Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1) ,etc.","description":"\u003cp data-mce-fragment=\"1\"\u003eProduct No.\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eLMA788Hu\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eOrganism Species\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eHomo sapiens (Human).\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eSample Type\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eserum, plasma, tissue homogenates and other biological fluids.\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eTest Method\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eDouble-antibody Sandwich\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eAssay Length\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e3.5h\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eDetection Range\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e0.01-10ng\/mL\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eSensitivity\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eThe minimum detectable dose of this kit is typically less than 0.003 ng\/mL.\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eUOM\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e1Plex 2Plex 3Plex 4Plex 5Plex 6Plex 7Plex 8Plex\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e \u003c\/p\u003e\n\u003cdiv class=\"product_left\"\u003e\n\u003ch3\u003eSpecificity\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThis assay has high sensitivity and excellent specificity for detection of Programmed Cell Death Protein 1 Ligand 1 (PDL1) ,etc..\u003cbr\u003eNo significant cross-reactivity or interference between Programmed Cell Death Protein 1 Ligand 1 (PDL1) ,etc. and analogues was observed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eRecovery\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eMatrices listed below were spiked with certain level of recombinant Programmed Cell Death Protein 1 Ligand 1 (PDL1) ,etc. and the recovery rates were calculated by comparing the measured value to the expected amount of Programmed Cell Death Protein 1 Ligand 1 (PDL1) ,etc. in samples.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003eRecovery range (%)\u003c\/td\u003e\n\u003ctd\u003eAverage(%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eserum(n=5)\u003c\/td\u003e\n\u003ctd\u003e87-101\u003c\/td\u003e\n\u003ctd\u003e92\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDTA plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e91-99\u003c\/td\u003e\n\u003ctd\u003e95\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eheparin plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e80-90\u003c\/td\u003e\n\u003ctd\u003e86\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3\u003ePrecision\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Programmed Cell Death Protein 1 Ligand 1 (PDL1) ,etc. were tested 20 times on one plate, respectively.\u003cbr\u003eInter-assay Precision (Precision between assays): 3 samples with low, middle and high level Programmed Cell Death Protein 1 Ligand 1 (PDL1) ,etc. were tested on 3 different plates, 8 replicates in each plate.\u003cbr\u003eCV(%) = SD\/meanX100\u003cbr\u003eIntra-Assay: CV\u0026lt;10%\u003cbr\u003eInter-Assay: CV\u0026lt;12%\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eLinearity\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Programmed Cell Death Protein 1 Ligand 1 (PDL1) ,etc. and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSample\u003c\/td\u003e\n\u003ctd\u003e1:2\u003c\/td\u003e\n\u003ctd\u003e1:4\u003c\/td\u003e\n\u003ctd\u003e1:8\u003c\/td\u003e\n\u003ctd\u003e1:16\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eserum(n=5)\u003c\/td\u003e\n\u003ctd\u003e86-99%\u003c\/td\u003e\n\u003ctd\u003e85-99%\u003c\/td\u003e\n\u003ctd\u003e93-101%\u003c\/td\u003e\n\u003ctd\u003e78-104%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDTA plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e82-97%\u003c\/td\u003e\n\u003ctd\u003e98-105%\u003c\/td\u003e\n\u003ctd\u003e89-98%\u003c\/td\u003e\n\u003ctd\u003e85-103%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eheparin plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e78-95%\u003c\/td\u003e\n\u003ctd\u003e90-99%\u003c\/td\u003e\n\u003ctd\u003e90-101%\u003c\/td\u003e\n\u003ctd\u003e98-105%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3\u003eStability\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.\u003cbr\u003eTo minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eReagents and materials provided\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"reagent_div\"\u003e\n\u003ctable class=\"reagent_table\"\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eQuantity\u003c\/td\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eQuantity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e96-well plate\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003ePlate sealer for 96 wells\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Mixed Standard\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003eStandard Diluent\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Mixed Magnetic beads (22#:PDL1)\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003eAnalysis buffer\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Mixed Detection Reagent A\u003c\/td\u003e\n\u003ctd\u003e1×120μL\u003c\/td\u003e\n\u003ctd\u003eAssay Diluent A\u003c\/td\u003e\n\u003ctd\u003e1×12mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDetection Reagent B (PE-SA)\u003c\/td\u003e\n\u003ctd\u003e1×120μL\u003c\/td\u003e\n\u003ctd\u003eAssay Diluent B\u003c\/td\u003e\n\u003ctd\u003e1×12mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSheath Fluid\u003c\/td\u003e\n\u003ctd\u003e1×10mL\u003c\/td\u003e\n\u003ctd\u003eWash Buffer (30 × concentrate)\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstruction manual\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch3\u003eAssay procedure summary\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003e1. Preparation of standards, reagents and samples before the experiment;\u003cbr\u003e2. Add 100μL standard or sample to each well,\u003cbr\u003e    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;\u003cbr\u003e3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;\u003cbr\u003e4. Wash plate on magnetic frame for three times;\u003cbr\u003e5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;\u003cbr\u003e6. Wash plate on magnetic frame for three times;\u003cbr\u003e7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product_reference\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eMagazine\u003c\/td\u003e\n\u003ctd\u003eCitations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChinese Journal of Cancer\u003c\/td\u003e\n\u003ctd\u003eLevel of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3937742\/\" target=\"_blank\"\u003eNCBI: PMC3937742\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeukemia.?\u003c\/td\u003e\n\u003ctd\u003eHigh level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24732592\" target=\"_blank\"\u003ePubmed:24732592\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes?Metab Res Rev.\u003c\/td\u003e\n\u003ctd\u003ePD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in Chile\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24816853\" target=\"_blank\"\u003ePubmed:24816853\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLancet Haematol\u003c\/td\u003e\n\u003ctd\u003eRatios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26686046\" target=\"_blank\"\u003ePubMed: 26686046\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEur J Cancer. \u003c\/td\u003e\n\u003ctd\u003eHigh levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27039170\" target=\"_blank\"\u003ePubmed:27039170\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Cancer Research and Clinical Oncology\u003c\/td\u003e\n\u003ctd\u003eSerum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/link.springer.com\/article\/10.1007\/s00432-016-2184-6\" target=\"_blank\"\u003earticle:10.1007\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Hematology \u0026amp; Oncology\u003c\/td\u003e\n\u003ctd\u003ePD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27737703\" target=\"_blank\"\u003epubmed:27737703\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLung Cancer.\u003c\/td\u003e\n\u003ctd\u003eHigh plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28212990\" target=\"_blank\"\u003epubmed:28212990\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncotarget\u003c\/td\u003e\n\u003ctd\u003eSoluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predictssurvival in advanced biliary tract cancer patients treated with palliative chemotherapy.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27780932\" target=\"_blank\"\u003epubmed:27780932\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncotarget\u003c\/td\u003e\n\u003ctd\u003eHigh post-treatment serum levels of soluble programmed cell death ligand 1 predict earlyrelapse and poor prognosis in extranodal NK\/T cell lymphoma patients.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27105512\" target=\"_blank\"\u003epubmed:27105512\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncotarget. \u003c\/td\u003e\n\u003ctd\u003eSoluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27566569\" target=\"_blank\"\u003epubmed:27566569\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer Immunol Immunother.\u003c\/td\u003e\n\u003ctd\u003eProgrammed death-ligand 1 and its soluble form are highly expressed in nasal natural killer\/T-cell lymphoma: a potential rationale for immunotherapy.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28349165\" target=\"_blank\"\u003epubmed:28349165\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeukemia\u003c\/td\u003e\n\u003ctd\u003eSoluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.nature.com\/leu\/journal\/v31\/n4\/full\/leu2016385a.html\" target=\"_blank\"\u003eleu2016385a\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicine\u003c\/td\u003e\n\u003ctd\u003ePlasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy.\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28207525\" target=\"_blank\"\u003epubmed:28207525\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAllergology International \u003c\/td\u003e\n\u003ctd\u003eInverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27617656\" target=\"_blank\"\u003epubmed:27617656\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicine\u003c\/td\u003e\n\u003ctd\u003ePlasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5319514\/\" target=\"_blank\"\u003ePMC5319514\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmerican Journal of Respiratory and Critical Care Medicine\u003c\/td\u003e\n\u003ctd\u003eSoluble Programed Death Receptor 1 Ligand (sPD-L1) in Pleural Fluid of Patients with Malignant Pleural Mesothelioma (MPM)\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.atsjournals.org\/doi\/pdf\/10.1164\/ajrccm-conference.2018.197.1_MeetingAbstracts.A4693\" target=\"_blank\"\u003ePdf:10.1164\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Lung Cancer\u003c\/td\u003e\n\u003ctd\u003eSoluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29859759\" target=\"_blank\"\u003ePubmed:29859759\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Rheumatology\u003c\/td\u003e\n\u003ctd\u003eIncreased levels of soluble programmed death ligand 1 associate with malignancy in patients with dermatomyositis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29419471\" target=\"_blank\"\u003ePubmed:29419471\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTranslational Oncology\u003c\/td\u003e\n\u003ctd\u003eHigh Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29698935\" target=\"_blank\"\u003ePubmed:29698935\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunology Letters\u003c\/td\u003e\n\u003ctd\u003eIncreased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0165247818302463\" target=\"_blank\"\u003ePubmed: 30236481\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Cancer Research and Clinical Oncology\u003c\/td\u003e\n\u003ctd\u003ePre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/link.springer.com\/article\/10.1007\/s00432-018-2758-6\" target=\"_blank\"\u003ePubmed: 30267213\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnals of Surgical Oncology\u003c\/td\u003e\n\u003ctd\u003eSoluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between …\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/link.springer.com\/article\/10.1245\/s10434-018-07112-x\" target=\"_blank\"\u003ePubmed: 30565045\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmerican Journal of Reproductive Immunology\u003c\/td\u003e\n\u003ctd\u003eIdentification of programmed cell death 1 and its ligand in the testicular tissue of mice\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/aji.13079\" target=\"_blank\"\u003ePubmed: 30578744\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePLoS One\u003c\/td\u003e\n\u003ctd\u003eClinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated …\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0212978\" target=\"_blank\"\u003ePubmed: 30807610\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEndocrine Connections\u003c\/td\u003e\n\u003ctd\u003eElevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/aop\/ec-19-0210.xml\" target=\"_blank\"\u003ePubmed: 31252406\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScientific Reports\u003c\/td\u003e\n\u003ctd\u003ePrognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6668419\/\" target=\"_blank\"\u003ePubmed: 31366979\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCritical Reviews in Oncology \/ Hematology\u003c\/td\u003e\n\u003ctd\u003eThe Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31675543\/\" target=\"_blank\"\u003ePubmed: 31675543\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePLoS One\u003c\/td\u003e\n\u003ctd\u003eClinical implications of APOBEC3A and 3B expression in patients with breast cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32176735\/\" target=\"_blank\"\u003ePubmed: 32176735\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancers\u003c\/td\u003e\n\u003ctd\u003ePredictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32085544\/\" target=\"_blank\"\u003ePubmed: 32085544\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eSerum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32054467\/\" target=\"_blank\"\u003ePubmed: 32054467\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLIVER INTERNATIONAL\u003c\/td\u003e\n\u003ctd\u003eThe prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32780918\/\" target=\"_blank\"\u003ePubmed: 32780918\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCANCER IMMUNOLOGY IMMUNOTHERAPY\u003c\/td\u003e\n\u003ctd\u003ePrognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32577816\/\" target=\"_blank\"\u003ePubmed: 32577816\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eSoluble PD-L1: a potential immune marker for HIV-1 infection and virological failure\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32443313\/\" target=\"_blank\"\u003ePubmed: 32443313\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer Immunol Immunother\u003c\/td\u003e\n\u003ctd\u003eThe clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33688997\" target=\"_blank\"\u003e33688997\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActa Biochim Biophys Sin\u003c\/td\u003e\n\u003ctd\u003ePrognostic prospect of soluble programmed cell death ligand-1 (sPD-L1) in cancer management\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34180502\/\" target=\"_blank\"\u003e34180502\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMBO J\u003c\/td\u003e\n\u003ctd\u003eMicroglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer's disease pathology\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34825707\/\" target=\"_blank\"\u003e34825707\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMol Pharm\u003c\/td\u003e\n\u003ctd\u003eA Novel Small Cyclic Peptide-Based 68Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34910492\/\" target=\"_blank\"\u003e34910492\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMol Hum Reprod\u003c\/td\u003e\n\u003ctd\u003eMacrophage Associated Immune Checkpoint CD47 Blocking Ameliorates Endometriosis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35404426\/\" target=\"_blank\"\u003ePubmed:35404426\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Nanobiotechnology\u003c\/td\u003e\n\u003ctd\u003eMicrobial hydrogen “manufactory” for enhanced gas therapy and self-activated immunotherapy via reduced immune escape\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35705974\/\" target=\"_blank\"\u003ePubmed:35705974\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicina\u003c\/td\u003e\n\u003ctd\u003eAssessment of the RANTES Level Correlation and Selected Inflammatory and Pro-Angiogenic Molecules Evaluation of Their Influence on CRC Clinical Features: A …\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35208526\/\" target=\"_blank\"\u003ePubmed:35208526\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product_relation\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eCatalog No.\u003c\/td\u003e\n\u003ctd class=\"td_2\"\u003eRelated products for research use of Homo sapiens (Human) Organism species\u003c\/td\u003e\n\u003ctd class=\"td_3\"\u003eApplications (RESEARCH USE ONLY!)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPA788Hu02\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/RPA788Hu02.html\"\u003eRecombinant Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003ePositive Control; Immunogen; SDS-PAGE; WB.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPA788Hu01\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/RPA788Hu01.html\"\u003eRecombinant Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003ePositive Control; Immunogen; SDS-PAGE; WB.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPA788Hu61\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/APA788Hu61.html\"\u003eActive Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eCell culture; Activity Assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEPA788Hu61\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/EPA788Hu61.html\"\u003eEukaryotic Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003ePositive Control; Immunogen; SDS-PAGE; WB.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePAA788Hu01\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/PAA788Hu01.html\"\u003ePolyclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB,ICC\/IF\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFAA788Hu01\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/FAA788Hu01.html\"\u003eAnti-Programmed Cell Death Protein 1 Ligand 1 (PDL1) Polyclonal Antibody\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eFlow cytometry.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFAA788Hu41\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/FAA788Hu41.html\"\u003ePE-Linked Anti-Programmed Cell Death Protein 1 Ligand 1 (PDL1) Polyclonal Antibody\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eFlow cytometry.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFAA788Hu51\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/FAA788Hu51.html\"\u003eAPC-Linked Anti-Programmed Cell Death Protein 1 Ligand 1 (PDL1) Polyclonal Antibody\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eFlow cytometry.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFAA788Hu81\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/FAA788Hu81.html\"\u003eFITC-Linked Anti-Programmed Cell Death Protein 1 Ligand 1 (PDL1) Polyclonal Antibody\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eFlow cytometry.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA788Hu22\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA788Hu22.html\"\u003eMonoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAA788Hu22\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/RAA788Hu22.html\"\u003eRecombinant Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IF; ICC; IHC; IP; FCM.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA788Hu21\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA788Hu21.html\"\u003eMonoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA788Hu23\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA788Hu23.html\"\u003eMonoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA788Hu24\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA788Hu24.html\"\u003eMonoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA788Hu25\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA788Hu25.html\"\u003eMonoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA788Hu27\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA788Hu27.html\"\u003eMonoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA788Hu29\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/MAA788Hu29.html\"\u003eMonoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC; IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAA788Hu21\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/RAA788Hu21.html\"\u003eRecombinant Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IF; ICC; IHC; IP; FCM.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLAA788Hu72\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/LAA788Hu72.html\"\u003eBiotin-Linked Monoclonal Antibody to Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eWB; IHC; ICC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFAA788Hu82\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/FAA788Hu82.html\"\u003eFITC-Linked Anti-Programmed Cell Death Protein 1 Ligand 1 (PDL1) Monoclonal Antibody\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eFlow cytometry.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWEA788Hu\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/WEA788Hu.html\"\u003eWide-range ELISA Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eEnzyme-linked immunosorbent assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEA788Hu\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/SEA788Hu.html\"\u003eELISA Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eEnzyme-linked immunosorbent assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCA788Hu\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/SCA788Hu.html\"\u003eCLIA Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eChemiluminescent immunoassay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLMA788Hu\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/LMA788Hu.html\"\u003eMagnetic Luminex Assay Kit for Programmed Cell Death Protein 1 Ligand 1 (PDL1) ,etc.\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eMagnetic Luminex Assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePSA788Hu01\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/PSA788Hu01.html\"\u003eAntibody Pair for Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKSA788Hu01\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/KSA788Hu01.html\"\u003eELISA Kit DIY Materials for Programmed Cell Death Protein 1 Ligand 1 (PDL1)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eMain materials for \"Do It (ELISA Kit) Yourself\".\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e","brand":"Cloud-clone","offers":[{"title":"0.01-10ng\/mL \/ 96T \/ typically less than 0.003 ng\/mL","offer_id":47567394963736,"sku":"LMA788Hu","price":756.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/products\/LMA788Hu_193f742b-b10b-4c5f-92ec-194e5612aa2f.jpg?v=1705958480","url":"https:\/\/danabiosci.com\/products\/new-product-615951","provider":"Dana Bioscience","version":"1.0","type":"link"}